Delivery Order SPE2DB24D1205-SPE2DB24FCQVS
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order with a Firm Fixed Price of $10,434.52 for the supply of DUPIXENT 300 MG/2 ML PEN 2ML medication. The contract, awarded by the Defense Logistics Agency (DLA), has an ultimate completion date of April 29, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $12,370.52 for the supply of 4560815979 - DUPIXENT 300 MG/2 ML SYRINGE 2ML. The contract is a firm-fixed-price agreement with an ultimate completion date of May 4, 2023. The award was made by the Defense Logistics Agency (DLA) Troop Support Medical, a division of the Department of Defense (DoD). Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $26,542.08 for the supply of Dupixent 200 mg/1.14 ml syringes. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $6,273.85 for the supply of DUPIXENT 300 MG/2 ML SYRINGE 2ML medical products. The award was made by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense, to support military healthcare programs. The contract has an ultimate completion date of December 7, 2023. Amerisourcebergen is a major pharmaceutical distributor that holds significant...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a $41,935.36 firm fixed-price delivery order placed by the Defense Logistics Agency (DLA). The contract covers the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a period of performance through February 15, 2024. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $13,151.25 Firm Fixed Price delivery order is for the supply of DUPIXENT 200 MG/1.14 ML SYRING 1.14ML, a specialty pharmaceutical product. The contract has an ultimate completion date of November 2, 2022. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order (DO) valued at $9,917.28 for the supply of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, with a completion date of February 12, 2024. The contract is a Firm Fixed Price arrangement with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $3,304.72, is for the delivery of DUPIXENT 200 MG/1.14 ML SYRING 1.14ML, a specialty pharmaceutical product. The contract has an ultimate completion date of January 6, 2023 and is structured as a firm fixed-price delivery order. This award is not associated with any set-aside designation, indicating open competition....
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $27,100.61 firm fixed-price delivery order is for the supply of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The contract has an ultimate completion date of May 6, 2024. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the...
- The U.S. government awarded a Delivery Order contract worth $5,441.90 to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., to provide DUPIXENT 300 MG/2 ML SYRINGE 2ML to the Defense Logistics Agency (DLA) Troop Support Medical. This Delivery Order contract has a completion date of December 7, 2023 and is a Firm Fixed Price contract type. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB24FCQVSDelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $22,504.08 for the supply of DUPIXENT 200 MG/1.14 ML SYRING 1.14ML. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of April 29, 2024. The contract is a Firm Fixed Price arrangement with no set-aside designation, indicating open competition. Amerisourcebergen, as a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veteran healthcare programs, and other federal medical institutions worldwide. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.5k | 4/26/24 |